We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Revolutionary Multi-Cancer Early Detection Test Offers Affordable Screening Tool for LMICs

By LabMedica International staff writers
Posted on 20 Jun 2023
Print article
Image: The blood-based pan cancer early detection test utilizes NGS and AI (Photo courtesy of Freepik)
Image: The blood-based pan cancer early detection test utilizes NGS and AI (Photo courtesy of Freepik)

Cancer claimed almost 10 million lives globally last year, with a majority of the cases detected too late for effective treatment. While early screening tests for cancer can save lives, these clinically validated tests only cover a few types, such as lung, colon, liver, breast, cervix, and prostate cancers, and their detection rates and specificity are limited. Conventional cancer screening technologies often prove unsuitable for low- and middle-income countries (LMICs) due to their cost, complexity, and reliance on substantial medical infrastructure. Now, a ground-breaking multi-cancer early detection (MCED) test, driven by artificial intelligence (AI) technology, could potentially save numerous lives by identifying cancer at earlier stages. The MCED test could revolutionize early cancer detection in LMICs.

OncoSeek developed by SeekIn Inc. (Shenzhen, China) is an MCED test based on the analysis of protein tumor markers (PTMs). It can simultaneously detect characteristic tumor markers for different types of cancers. Utilizing AI, the test can differentiate between individuals with cancer and those without by calculating a probability of cancer (POC) index. This calculation is based on the plasma levels of seven PTMs, as well as the gender and age of the subjects. With only a blood draw required at screening sites, OncoSeek is both affordable and accessible, making it a sustainable option in LMICs.

A recent study showed that OncoSeek considerably reduces the rate of false positives compared to traditional clinical methods. The study involved nearly 10,000 participants from China and the United States, consisting of 1,959 cancer patients and 7,423 healthy individuals. Each participant had one tube of peripheral blood collected for the detection of seven specific proteins using a standard clinical electrochemiluminescence immunoassay analyzer. After PTMs were quantified, OncoSeek, using AI, distinguished cancer patients from non-cancer individuals, calculated the POC index and predicted the possible affected tissue of origin (TOO) for those with detected cancer signals in blood.

The test demonstrated a sensitivity of 51.7%, and a specificity of 92.9%, resulting in an overall accuracy of 84.3%, with a sensitivity of 49.5% in stage I and II patients. For the detection of nine common cancer types, which account for approximately 59.2% of annual global cancer deaths, sensitivities ranged from 37.1% to 77.6%. The overall accuracy of TOO prediction in true positives is 66.8%, which could be a helpful tool in clinical diagnostic workups. OncoSeek, offering a non-invasive, efficient, and cost-effective solution for MCED, received CE-IVD Mark approval in September 2022.

Related Links:
SeekIn Inc. 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.